There are various techniques used for determining the chromosomal makeup of a foetus, but the only diagnostic test currently available involves karyotyping, which is done by means of an invasive procedure such as an amniotic fluid test. NIPT is very effective for determining the risk that a foetus will be born with certain genetic abnormalities and has become widely used in recent years. Your doctor will be able to explain the different options available to you for screening for foetal chromosomal abnormalities. The team at the National Centre of Genetics, which is part of the LNS, is able to accompany patients throughout the process, from the moment blood is taken through to when any further testing is done or you attend a genetic consultation at our centre. You should remember that the decision to have this screening test done is very personal to each individual or couple.
Non-invasive prenatal testing (NIPT) refer to a particular type of test. Its purpose is to screen for the most common chromosomal abnormalities in foetuses, primarily trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome). This test analyses fragments of foetal DNA circulating in a pregnant woman’s blood. It is very reliable and presents no risk whatsoever to the foetus.
Each cell in the body has DNA, which contains all of a person’s genetic information. This information is organised into 23 pairs of chromosomes: 22 autosome pairs (1 to 22) and two sex chromosomes, namely XX or XY.
Female karyotype 46,XX
Male karyotype 46,XY
A trisomy refers to the presence of 3 copies of a chromosome, instead of two.
Karyotype showing trisomy 21 : 47,XY,+21
During pregnancy, fragments of foetal DNA from the placenta (cytotrophoblast) enter the mother’s bloodstream. These fragments are free-floating and not within cells, and are called cell-free foetal DNA (cffDNA). Through a simple blood test done at a laboratory, the fragments of cffDNA are counted to look for the presence of an extra chromosome 21, 13 or 18. This avoids invasive testing (such as an amniotic fluid test), which carries a greater risk for the foetus and results in miscarriages in 0.1-0.5% of patients.
The method used to count cffDNA is high-throughput sequencing. There are two different approaches:
Sequencing focuses solely on the chromosomes of interest, namely 21, 18 and 13.
Sequencing is more extensive and not limited to the chromosomes of interest. This technique also allows number abnormalities of chromosomes 13, 18 and 21 to be detected. It is used for twins or where there is a low volume of cffDNA in the mother’s blood. Moreover, in rare cases this technique may reveal chromosomal abnormalities which were not initially being screened for.
The National Centre of Genetics uses an automated, CE-IVD-certified, whole-genome technique: Veriseq V2 Illumina®
This screening test is requested for pregnant women by physician in charge of monitoring their pregnancy, based on their medical history, and may be done from 12 weeks gestation (10th week of pregnancy) onwards.
It is not suitable for investigating abnormalities revealed on ultrasound scans, particularly nuchal translucency of > 3.5mm in the first trimester. In practice, this test should be done following the 1st trimester scan. Before it is performed, a specific form must be filled out by the doctor requesting the test and the patient, which must be sent to the Laboratoire National de Santé along with a blood sample.
NIPT is currently free of charge for patients covered by the CNS. Patients who are not eligible for reimbursement by the CNS will be billed for the test. The price is available upon request.
NIPT may be done from 10 weeks gestation onwards, but ideally should be done from 12 weeks gestation, following the 1st scan. However, it may be recommended throughout the pregnancy. This test does not require fasting beforehand and you may have the blood taken at your normal laboratory. However, you can also have it taken at the LNS.
All the stages of the test are overseen by the team of the National Center of Genetics (cytogenetic team in collaboration with the technical platform of molecular biology, bioinformatics and sequencing), made up of experienced technical, administrative and medical personnel, specialised in cytogenetics.
Results are sent solely to the doctor who requested the test 7 to 10 days after the LNS receives your blood sample. They are never sent directly to patients.
In the event of a:
Positive result:
This means there is a high probability that the foetus has trisomy 21, 13 or 18. Nevertheless, NIPT is a screening test and the relevant professional bodies recommend having a positive NIPT result confirmed by way of an invasive diagnostic test (primarily an amniotic fluid test). Your gynaecologist will talk you through the results and next steps.
The cytogenetics team will analyse the sample of amniotic fluid taken and interpret the results. You may also be asked to attend a genetic consultation with our team.
Negative result:
This means that the probability of the foetus having trisomy 21, 13 or 18 is very low. In this case, your pregnancy will be monitored as planned.
Inconclusive result:
This means that it is not possible to reliably determine if the foetus has trisomy 13, 18 or 21. Inconclusive results are rare (around 3% of cases), but may occur for example when there is not enough cell-free foetal DNA (cffDNA) circulating in the blood sample taken from the mother. The proportion of cffDNA in the mother’s blood is known as the foetal fraction and is determined by many factors, including her BMI, if she is taking certain blood thinners, etc. Depending on your medical history, your gynaecologist may recommend you repeat the test or have further tests done.
Under no circumstances does having NIPT mean you do not have to go to your prenatal scans or attend check-ups with your obstetrician. This test is not a substitute for having your 1st trimester scan.
The NIPT performed by the LNS is very reliable in terms of sensitivity and specificity.
| Trisomie 21 | Trisomie 18 | Trisomie 13 | |
|---|---|---|---|
| Sensibility | >99,9% | >99,9% | >99,9% |
| Specificity | 99,9% | 99,9% | 99,9% |
Sensitivity and specificity of the VeriSeq NIPT Solution v2 in a basic screening mode, for singleton pregnancies
Non-invasive prenatal testing screens for abnormalities in the number of chromosomes. It is unable to detect polyploidies (such as triploidy), balanced chromosomal rearrangements (exchanges of chromosomal fragments without any loss or gain of material), or point mutations.
Monday-Friday:
7.30 – 9.00 : without appointment
Adress:
Laboratoire national de santé
1, rue Louis Rech
L-3555 Dudelange
NIPT request form:
Download the form
Blood samples are received from Monday to Friday
Sampling and storage protocol for the NIPT test:
Download the protocol
Necessary documents:
To order Streck tubes, please get in touch with the LNS store at LNSMagasin@lns.etat.lu
Download the order form for the Streck tubes
For all queries relating to NIPT, please get in touch with the constitutional cytogenetics team at the National Center of Genetics.